Antidepressants for Depression: Benefits, Risks, and Treatment Decisions
Author: Angela Bogdanova · Published: October 8, 2026 · Editorial Policy
Research cluster: Depression & Depressive Disorders · Written by Artificial Sapiens
Antidepressants are medications used to treat major depressive disorder and some other conditions. For a person with clinically significant unipolar depression, the decision to start, continue, change, or stop medication depends on the severity and duration of illness, previous response, medical history, patient preferences, adverse effects, and access to other effective care. A well-designed treatment plan sets expectations before the first prescription, monitors outcomes after treatment begins, and revisits both benefits and burdens over time.
Research establishes that antidepressants outperform placebo on average in randomized trials of adults with major depressive disorder. The average benefit cannot predict the exact result for an individual, and meaningful improvement may require a different medication, psychotherapy, combined treatment, or specialist reassessment. The 2018 network meta-analysis of 21 antidepressants and the VA/DoD guideline for major depressive disorder provide important foundations for interpreting medication efficacy and choice.
This guide examines antidepressants specifically as a treatment decision for depression. For the complete clinical pathway, see Depression Treatment: Therapy, Medication, and Other Options. General medication classification across different psychiatric diagnoses belongs to the separate medication encyclopedia.
I. What antidepressants treat and what a prescription means
An antidepressant is a pharmacological intervention intended to reduce depressive symptoms and support functional recovery. In this article, the main condition is major depressive disorder (MDD), sometimes called unipolar depression. A major depressive episode is a time-limited clinical syndrome that may occur in MDD or bipolar disorder. A depressed mood is a symptom; it is not equivalent to either an episode or a diagnosis. Persistent depressive disorder involves a chronic pattern of depressive symptoms and requires its own assessment. Clinical decisions should follow an evaluation of syndrome, impairment, duration, severity, history, and competing explanations, as described by the National Institute of Mental Health and the VA/DoD guideline.
A positive depression-screening questionnaire can indicate that a person needs evaluation; it cannot, by itself, establish major depressive disorder or justify a specific drug. History should address prior depression, medication and psychotherapy trials, substance use, sleep, medical illnesses, possible pregnancy, psychotic symptoms, and safety. See Depression Diagnosis: What a Clinical Evaluation Includes.
Antidepressants are also prescribed for anxiety disorders and some pain syndromes, but evidence for one indication does not automatically transfer to another. A drug may have several regulatory indications, off-label uses, different doses, and different expected outcomes. The question here is whether a particular medication is a good choice for a particular depressive presentation.
II. Do antidepressants work for depression?
The evidence for short-term symptom reduction is substantial. Cipriani and colleagues compared 21 medications across 522 double-blind trials involving more than 116,000 participants with adult major depressive disorder. All assessed antidepressants were more effective than placebo for the study's primary response outcome, while effectiveness and acceptability varied. These are group-level estimates drawn mainly from trials of acute treatment, and the analysis does not establish that one agent is best for every patient or that all long-term outcomes are settled. Cipriani et al., The Lancet.
A response generally means a substantial reduction in depressive symptoms, commonly operationalized in research as a decrease of at least 50% on a specified rating scale. Remission means symptoms are reduced below an established threshold and functioning is substantially restored. Response and remission are different endpoints. A person may improve meaningfully but still have insomnia, anhedonia, poor concentration, or residual disability. Research percentages must be interpreted in relation to these endpoint definitions rather than presented as individual promises.
Absolute improvement depends on baseline risk, severity, diagnostic precision, comparator treatment, adherence, and length of follow-up. Placebo responses in depression trials are often substantial. For patients with less severe depressive symptoms, the choice between medication, structured psychotherapy, guided interventions, or monitored active care becomes particularly sensitive to individual preferences and likely harms. The NICE guideline NG222 recommends that antidepressants should not routinely be first-line treatment for less severe depression unless that is the informed preference of the person, whereas they remain one evidence-based first-line option for more severe depression.
Benefits extend beyond a rating-scale score when treatment works. People may regain their ability to get out of bed, enjoy relationships, maintain attention, work, study, eat regularly, sleep more consistently, and participate in daily life. These functional outcomes deserve explicit follow-up. Their improvement is influenced by psychotherapy, social conditions, comorbid illness, and practical support alongside medication.
III. When medication is a reasonable first treatment
Treatment is selected through a shared evaluation of severity, risk, persistence, previous episodes, accessible treatments, and what the patient values. For less severe depression, evidence-based talking therapy, guided self-help, behavioral activation, exercise programs, and other appropriate measures may be reasonable initial choices, with medication considered when preferred or clinically indicated. For more severe or functionally impairing major depression, antidepressants, psychotherapy, or their combination may be offered according to the clinical picture. NICE NG222; VA/DoD MDD guideline.
Combined psychotherapy and medication can be particularly worth discussing when depression is severe, persistent, or recurrent, when psychosocial difficulties maintain symptoms, or when a single approach has been insufficient. VA/DoD suggests combined treatment for severe, persistent, or recurrent major depressive disorder. A person can also choose medication while awaiting therapy, or psychotherapy without medication when it is clinically appropriate and preferred. VA/DoD recommendations.
Clinical urgency matters. Psychotic depression, inability to maintain basic hydration or nourishment, catatonia, severe agitation, or acute suicide risk can require prompt specialist or emergency assessment. Standard outpatient antidepressant initiation alone may be insufficient in such situations. A rapid deterioration or immediate threat to safety warrants local emergency services; in the United States, 988 is a suicide and crisis support contact, and 911 is appropriate for immediate danger. The specialist management of suicidality has its own care pathway.
IV. Which antidepressant might be chosen?
The commonly prescribed groups include selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine reuptake inhibitors (SNRIs), bupropion, mirtazapine, vortioxetine, vilazodone, tricyclic antidepressants, and monoamine oxidase inhibitors. Fluoxetine, sertraline, and escitalopram are examples of SSRIs; venlafaxine, duloxetine, and desvenlafaxine are SNRIs. Different agents have different pharmacology, approved indications, interaction profiles, availability, and tolerability. The FDA's depression medicines overview and the VA/DoD guideline outline major options.
1. SSRIs and SNRIs
SSRIs are commonly considered when starting medication for adult depression because many are supported by large clinical evidence bases and are generally easier to use than older high-toxicity alternatives. Common adverse effects can include nausea, altered sleep, headache, sweating, agitation, and sexual dysfunction. SNRIs share many of these issues; some can additionally affect blood pressure or heart rate, depending on the agent and dose. A medication's suitability depends on the whole health picture rather than its class name. FDA depression medicines.
2. Bupropion and mirtazapine
Bupropion may be considered when particular concerns include sexual adverse effects or fatigue, although its activating effects, seizure-related contraindications, and potential interaction or tolerability issues require screening. Mirtazapine may appeal in some clinical contexts involving insomnia or low appetite but often causes sedation, increased appetite, and weight gain. A 2025 systematic review found evidence for those common mirtazapine harms but very low certainty for serious rare events. Kamp et al., BMC Psychiatry.
3. Tricyclics, MAOIs, and other agents
Older tricyclic antidepressants and monoamine oxidase inhibitors remain clinically important for selected situations, often after previous treatment difficulties or under specialist care. Their distinct interaction risks, cardiovascular concerns, dietary restrictions for some MAOIs, and overdose toxicity make them inappropriate as casual substitutes. The NICE guideline specifically flags the danger of tricyclics in overdose and the need for special precautions when switching to or from MAOIs.
4. Individual drugs versus class averages
Clinical studies do not support choosing a medication solely from a generic ranking of “best antidepressants.” A prior good response, family history of response, current medications, sleep, anxiety, sexual functioning, appetite, cardiovascular history, seizure risk, kidney and liver function, availability, cost, and the patient's priorities all matter. Trials can show average comparative effects, but personal response remains uncertain. A clinician should explain why an agent fits the specific case and what would lead to reconsideration. Cipriani et al.; VA/DoD.
V. How long does it take an antidepressant to work?
A medication may cause side effects in its first days, while improvement in depressive symptoms usually develops over subsequent weeks. Some people notice changes in sleep, appetite, anxiety, or energy earlier than changes in mood or pleasure. Improvement should be assessed over a meaningful interval at a therapeutic dose, while also recognizing serious early adverse reactions. NICE advises that people should ordinarily see their first review within two weeks of starting medication, and within one week for ages 18–25 or when suicide risk is a particular concern. A response, if treatment is going to work, is usually apparent within about four weeks, although later response and further treatment adjustments are common. NICE NG222.
A treatment trial needs an agreed definition of “adequate”: dose, duration, adherence, and tolerability. A person who stopped after several days because of nausea has not had the same exposure as someone who took a therapeutic dose consistently for weeks. Conversely, insisting indefinitely on a medication with negligible benefit and substantial harm is not good treatment. At follow-up, clinician and patient should examine symptom change, function, side effects, missed doses, psychosocial stressors, and diagnostic uncertainty.
The prescriber may recommend continuing, gradually adjusting the dose, changing medications, adding or switching to evidence-based psychotherapy, or obtaining specialist input. Medication changes need individualized supervision because drug interactions, washout periods, withdrawal, and serotonin toxicity can occur. NICE further-line treatment recommendations.
VI. Common antidepressant side effects and what they mean
Side effects are experienced outcomes, not proof that a medication is dangerous for every user. Their incidence and severity vary across drugs, doses, patients, treatment duration, and research methods. A discussion before treatment should name the effects that matter most to the individual, state what can be monitored, and agree on a response plan. FDA depression medicines.
1. Gastrointestinal effects, headache, and sweating
Nausea, diarrhea or constipation, dry mouth, headache, and sweating can emerge early. Some effects diminish with time; others persist or lead a patient to change therapy. The response depends on severity and the drug rather than a blanket instruction to endure symptoms. Severe vomiting, dehydration, rash, bleeding, or other medically concerning changes require prompt clinical assessment.
2. Sleep, activation, and sedation
Some antidepressants are activating and may temporarily worsen restlessness or insomnia; others are sedating and can impair daytime alertness. The underlying depression may itself cause both insomnia and excessive sleep, complicating attribution. The timing of a new symptom relative to a dose change helps assessment, but a prescriber should also consider anxiety, substances, other medicines, and emerging bipolar symptoms. FDA; NICE.
3. Sexual functioning and emotional changes
Reduced libido, delayed orgasm, erectile difficulties, and altered arousal can be clinically important. Depression itself can impair sexual functioning, so changes should be discussed with a baseline history and follow-up. Some people also describe emotional blunting or feeling less able to experience positive and negative emotions. This experience deserves careful evaluation because it may reflect medication effects, residual depressive symptoms, or both. People should be invited to bring it up without embarrassment; decisions may include dose review, switching treatment, or other clinician-directed approaches. FDA adverse-effect overview.
Post-discontinuation sexual symptoms have been reported, but their frequency, causes, and individual prognosis remain uncertain. Evidence is insufficient for a simple numerical prediction for every patient. Transparent counseling distinguishes well-established treatment-emergent dysfunction from unresolved long-term estimates.
4. Weight and metabolic effects
Weight gain or loss may reflect appetite, symptom recovery, diet, activity, sleep, duration of exposure, or direct treatment effects. A large 2024 observational target-trial emulation found differences in weight change among commonly used agents, with lower average gain for bupropion and greater average gain for some other medications compared with sertraline. Observational comparisons cannot eliminate every source of confounding. Medication-induced weight change study.
A 2025 systematic review and network meta-analysis of 151 clinical trials plus 17 FDA reports found meaningful differences among 30 antidepressants for short-term physiological outcomes, including weight, heart rate, and blood pressure. It also emphasized the short median follow-up in the pooled trials. Monitoring decisions should therefore reflect the specific medication and the patient's cardiometabolic health, without treating a single ranking as a personal prediction. Pillinger et al., The Lancet.
VII. Serious and uncommon safety issues
A medication risk review should distinguish common discomfort from events requiring urgent assessment. Relevant concerns can include suicidal thoughts or behavioral activation early in treatment, mania or hypomania, serotonin syndrome, significant bleeding, low sodium, seizures, rhythm abnormalities, and clinically consequential drug interactions. Which of these applies depends on the exact medication, age, medical conditions, co-prescriptions, and dose. Product-specific labeling matters more than a generic list. FDA depression medicines.
1. Suicidal thoughts and the boxed warning
In short-term studies, antidepressants increased the risk of suicidal thoughts and behaviors in children, adolescents, and young adults compared with placebo. FDA boxed warnings call for close monitoring, particularly during early treatment and dose changes. The warning does not mean every treated young person will become suicidal, and untreated depression itself carries serious risks. An individualized benefit–risk plan is essential. The FDA prescribing information for fluoxetine describes the age-dependent warning; NICE NG222 recommends early follow-up for adults aged 18–25 and for higher-risk patients.
Any new or worsening suicidal thoughts, severe agitation, impulsivity, or marked behavioral changes after medication initiation warrant immediate contact with a responsible clinician. An immediate risk of harm requires emergency services. A clinician should also assess suicidality before medication is started and at appropriate intervals, rather than equating medication use with adequate safety planning.
2. Mania, hypomania, and mixed presentations
An antidepressant may be prescribed to someone whose depression is part of bipolar disorder that has not yet been recognized. A history of unusually elevated or irritable mood, markedly reduced need for sleep, accelerated thoughts, increased activity, excessive risk-taking, or previous treatment-related activation deserves careful exploration. Manic or hypomanic episodes and mixed features can materially change treatment choice. A screening questionnaire can inform evaluation but cannot establish or rule out bipolar disorder. If a patient develops marked activation or manic symptoms during treatment, they need prompt clinical reassessment. VA/DoD assessment and treatment guidance.
3. Serotonin syndrome and dangerous interactions
Serotonin syndrome is a potentially serious drug-related toxicity, especially relevant when serotonergic medicines are combined inappropriately or interacting doses are changed. Symptoms can include agitation, confusion, fever, sweating, tremor, diarrhea, muscle rigidity, hyperreflexia, or clonus. A rapidly developing combination of altered mental state, autonomic instability, and neuromuscular findings requires urgent medical assessment. The risk profile differs across medications, and switching rules matter. NICE medication-interaction guidance.
Other important interactions include bleeding risks with some medications used alongside SSRIs or SNRIs and medication-specific concerns involving QT interval, seizures, and liver function. Alcohol, recreational substances, herbal products such as St. John's wort, supplements, and over-the-counter medicines should be disclosed to the prescriber. Do not combine or adjust serotonergic medicines without qualified guidance. FDA.
VIII. How clinicians compare potential benefits and harms
Shared decision-making makes the tradeoffs explicit. A useful consultation covers the diagnosis and its certainty, expected gains in symptoms and functioning, available psychotherapy, side effects that matter most to the patient, interaction risks, timing of review, financial and access barriers, and a stopping or switching plan. NICE recommendations on choice of treatments.
A patient might prioritize remaining alert at work, minimizing sexual side effects, protecting sleep, avoiding weight gain, keeping a stable routine, managing other chronic illnesses, or avoiding complex monitoring. These priorities can legitimately affect drug selection even when average efficacy differences are modest. In a large pragmatic care system, access to follow-up can matter as much as a theoretical pharmacological preference.
Treatment decisions are revisable. If the patient receives benefit and side effects are manageable, continuation may be appropriate. If there is partial response, the clinician may examine adherence, dose, psychotherapy access, and comorbidity. If there is little benefit or unacceptable harm, switching or a different treatment pathway can be reasonable. The record should explain what the trial demonstrated rather than labeling every imperfect outcome as “resistant depression.” VA/DoD MDD guideline.
IX. Monitoring after a new prescription
Monitoring begins with a baseline understanding of mood, anhedonia, sleep, appetite, energy, concentration, functioning, safety, relevant physical health, and adverse effects. Patients and clinicians can track changes at agreed intervals using clinical discussion and, where useful, validated scales. A scale is a measurement aid, not a substitute for diagnosis or professional interpretation. NICE NG222.
An early review should ask whether the medication was started and taken as intended, whether side effects are tolerable, whether suicidal thoughts or agitation have changed, and whether there are early signs of benefit. Follow-up should continue over the acute trial and longer-term care. If a patient misses doses repeatedly, the answer may involve practical barriers, poor tolerability, or a change of plan, rather than blaming the patient.
Patients should know whom to contact for urgent problems, what changes require same-day assessment, and when the next routine evaluation is scheduled. Prescribing without a practical follow-up route makes it harder to interpret both efficacy and harm.
X. How long should treatment continue after improvement?
The acute phase aims to reduce active depressive symptoms. Continuation treatment aims to preserve remission and lower the likelihood of near-term return of symptoms. Longer-term maintenance may be relevant for recurrent, severe, persistent, or otherwise high-relapse-risk depression. The plan should review recurrence history, prior discontinuation experience, residual symptoms, patient goals, and ongoing adverse effects. NICE advises that treatment may need to continue for at least six months after remission, with regular review, and that some patients benefit from longer continuation. NICE NG222.
In the ANTLER trial in primary care, 39% of people randomized to maintain their antidepressant and 56% randomized to taper and discontinue experienced depressive relapse over 52 weeks. This result applies to the study's selected participants who felt well enough to consider stopping, not to everyone with depression. It also does not establish that indefinite medication is always necessary. Lewis et al., New England Journal of Medicine.
The decision to continue should consider likely benefit alongside the patient's experience of sexual effects, weight, sleep, interactions, medical burden, and personal preference. Relapse prevention can involve psychotherapy and self-management strategies as well as medication. Successful remission is an achievement to be sustained and reassessed, not a reason to stop medication suddenly.
XI. Antidepressant withdrawal and discontinuation
Withdrawal, also called antidepressant discontinuation symptoms, refers to symptoms that may emerge after a dose reduction, missed doses, or stopping treatment. Dizziness, electric-shock-like sensations, nausea, altered sleep, irritability, anxiety, headache, and flu-like feelings are examples. Symptoms vary in intensity and duration, and may sometimes be severe or prolonged. NICE NG222.
Withdrawal and depressive relapse require different interpretations. Withdrawal often begins relatively soon after a reduction and may feature distinctive physical or sensory symptoms; relapse more often resembles the original depressive syndrome and follows a different course. Their presentations can overlap. The prescriber should evaluate timing, symptoms, prior illness, and medication history instead of confidently labeling every worsening mood as relapse or withdrawal.
A 2024 Lancet Psychiatry meta-analysis examined discontinuation symptoms across study designs and estimated that approximately one in six to seven people experienced symptoms directly attributable to stopping an antidepressant beyond nonspecific symptoms; estimates varied by design and medication. A separate 2025 JAMA Psychiatry synthesis of randomized trials found that stopping antidepressants produced, on average, roughly one additional symptom compared with comparator groups. These studies answer related but different questions, and neither establishes the probability of prolonged withdrawal for an individual. Henssler et al., 2024; 2025 discontinuation review.
Tapering should be planned jointly with the prescriber. NICE recommends reducing doses in stages, often making smaller proportional reductions as doses become low, adjusting the pace to symptoms and formulation, and recognizing that tapering may take weeks or months. Medications with relatively short half-lives, including paroxetine and venlafaxine, can require particular care; fluoxetine has a different pharmacokinetic profile. The plan is individualized, not a universal calendar. NICE stopping medication recommendations.
Do not abruptly stop or independently alter a prescribed antidepressant simply because symptoms improve or a side effect appears. Serious adverse reactions may require urgent treatment and rapid clinician-directed change, so the safest next step depends on the event. If withdrawal is severe, the clinician may review whether a temporary return to a previous dose and slower taper is appropriate. NICE NG222.
XII. What if the first antidepressant does not help?
Lack of improvement calls for structured reassessment. The clinician should examine whether the original diagnosis fits, whether bipolar disorder, psychosis, substance effects, a medical condition, insomnia, or other comorbidities require attention, whether an adequate trial occurred, and whether the person's life circumstances or treatment preferences have changed. VA/DoD; NICE NG222.
Options include dose optimization within safe licensed parameters, switching to another antidepressant, adding evidence-based psychotherapy, or specialist-guided augmentation. Treatment-resistant depression commonly refers to failure to obtain adequate benefit from at least two adequate antidepressant trials, although definitions differ across studies and settings. Two brief or poorly tolerated medication exposures do not automatically meet that standard.
Specialist treatments such as repetitive transcranial magnetic stimulation, electroconvulsive therapy, ketamine, and intranasal esketamine may be considered for selected depressive presentations. Their eligibility, monitoring, advantages, and risks are distinct from routine oral antidepressants. In the United States, the 2025 FDA label for intranasal esketamine includes treatment-resistant depression in adults as monotherapy or with an oral antidepressant, with required clinical supervision and monitoring; its effectiveness in preventing suicide has not been demonstrated. FDA Spravato prescribing information; VA/DoD advanced treatment recommendations.
A next-step decision benefits from a documented account of past doses, durations, adverse effects, functional response, psychotherapy exposure, and medical conditions. Referral for specialist assessment is appropriate when decisions exceed the scope of routine primary care.
XIII. Children, adolescents, young adults, and older adults
Prescribing for children and adolescents requires developmentally appropriate diagnosis, evidence-based psychotherapy planning, active family or caregiver involvement where appropriate, informed consent, and careful safety monitoring. Regulatory approval differs by age and indication. Fluoxetine and escitalopram have pediatric major-depression labeling for specified age groups, but a drug's authorization cannot substitute for clinical evaluation, and the FDA suicidality warning requires special attention. The American Academy of Pediatrics' adolescent depression treatment guideline was reaffirmed in 2025.
Young adults also warrant close attention to early treatment-emergent distress and suicidality. The monitoring recommendation for ages 18–25 should be visible in the follow-up plan. Older adults may have more complex medical conditions, multiple prescriptions, and increased sensitivity to hyponatremia, falls, sedating effects, bleeding, or cardiovascular effects. Age matters as part of individualized risk assessment, while symptom change and life functioning remain core treatment endpoints. NICE NG222; FDA medicines overview.
Pregnancy planning, pregnancy, breastfeeding, fertility, and postpartum mental health require a condition-specific, individualized review of both medication exposure and the risks of untreated depression. People should discuss pregnancy or reproductive plans with their clinicians before changing a prescribed medicine. The general decision principles here support that conversation; specialized perinatal prescribing belongs to its own clinical care domain. FDA medicines overview.
XIV. Antidepressants and other medical conditions
Coexisting cardiovascular disease, diabetes, chronic pain, epilepsy, kidney or liver disease, sleep disorders, and polypharmacy can change which antidepressant is safest or most convenient. Evidence from standard depression trials often underrepresents people with substantial physical comorbidity. A 2025 network meta-analysis specifically examined depression with physical health conditions and identified the limits of simply transferring estimates from otherwise healthier trial samples. De Luca et al., British Journal of Psychiatry.
Medication reconciliation should include prescribed drugs, over-the-counter treatments, supplements, and substances. Monitoring may involve blood pressure, weight, sodium levels, electrocardiography, or other tests when clinically relevant to a specific agent and patient. Such tests are targeted assessments rather than a universal requirement for every antidepressant prescription. FDA; Pillinger et al..
XV. Common misconceptions that change treatment decisions
“Antidepressants work immediately.” Symptom improvement often takes weeks, even when early physical effects occur. Monitoring over the first days remains important, particularly for activation, safety, or intolerance. NICE.
“If I need medication, my depression must be severe.” Medication may be chosen for various clinical reasons and informed preferences. Depression severity alone does not determine every patient's treatment, and people with serious depression can benefit from structured psychotherapy or combination treatment. NICE.
“The first prescription must be the right one.” Outcomes vary. A careful medication trial produces information about efficacy and tolerability that can guide the next decision. VA/DoD.
“Stopping antidepressants always causes withdrawal” and “withdrawal is imaginary” are both inaccurate. Symptoms are documented, vary among people and medications, and require a plan grounded in the particular case. 2024 systematic review; NICE.
“Antidepressants prove depression is a chemical imbalance.” Drug responsiveness does not establish a single causal model of depression. Depression is clinically heterogeneous, involving interacting biological, psychological, developmental, and social processes. Treatment mechanisms and illness mechanisms should be evaluated with their own evidence. See What Causes Depression? Risk Factors and Current Evidence.
“High-functioning depression” or “smiling depression” determines medication need. These are popular descriptive labels, not stand-alone DSM or ICD diagnoses. Clinical evaluation considers symptom profile, impairment, duration, and alternative explanations, including when someone continues working or appearing socially engaged.
XVI. Questions to ask before starting or changing an antidepressant
A productive appointment can establish: What clinical diagnosis is being treated, and how confident are we? What improvements would show this medicine is helping? What alternatives, including psychotherapy, are reasonable? What side effects or interactions are most important in my case? When will we review progress and safety? What happens if I feel worse, miss doses, or want to stop? What is the plan for maintaining improvement?
A patient can ask specifically about sexual effects, sleep, weight, blood pressure, pregnancy planning, other medicines, and cost. They can request written instructions for dose changes and urgent-care contacts. These questions support collaborative treatment and informed consent. NICE shared decision-making and monitoring recommendations.
XVII. Frequently asked questions
1. What is the best antidepressant for depression?
There is no universal best choice. Several medicines work better than placebo on average, but individual history, prior response, adverse effects, interactions, and preferences determine suitability. A prescriber can compare options using clinical trial evidence and the VA/DoD guideline.
2. Can mild depression improve without medication?
Yes. Evidence-based psychotherapy, guided self-help, behavioral activation, and supported care can be appropriate for less severe depression, while medication remains an option depending on informed preference and clinical circumstances. Persisting or worsening symptoms warrant reassessment. NICE.
3. How soon should I notice a difference?
Some effects are noticeable early, while a meaningful antidepressant response often unfolds over several weeks. NICE advises monitoring and a formal review early in treatment, typically within two weeks, sooner when age or suicide-risk concerns warrant it. NICE.
4. What if I feel emotionally numb?
Tell the prescriber. Emotional blunting can be reported during medication treatment, but residual depression and other factors also require consideration. The clinician can assess the pattern and discuss alternatives rather than assuming an isolated cause. FDA medicine side-effect information.
5. Can antidepressants increase suicidal thoughts?
In short-term trials, the FDA identified increased risk of suicidal thoughts and behaviors among children, adolescents, and young adults relative to placebo. Close monitoring is important for all ages, particularly after starting or changing treatment. New or worsening suicidal thoughts require prompt clinical evaluation. FDA fluoxetine label.
6. Can I drink alcohol while taking an antidepressant?
Alcohol may worsen depression, interfere with treatment goals, or interact with medication-specific sedating and other effects. Ask the prescriber or pharmacist about the exact medicine, your drinking pattern, and any additional health conditions. FDA depression medicines.
7. Can I stop when I feel better?
Improvement is usually followed by continuation care to reduce relapse risk. Stopping should be planned, typically through a staged taper, with review of withdrawal risk and recurrence history. NICE NG222; ANTLER trial.
8. Is antidepressant withdrawal the same as addiction?
Withdrawal symptoms can occur after discontinuation, but that fact alone does not establish addiction, which involves a different pattern of compulsive use and related behaviors. Dose adaptation, withdrawal, tolerance, treatment response, and relapse are separate clinical concepts. NICE stopping guidance.
9. Do antidepressants treat bipolar depression in the same way?
Bipolar depression requires a distinct diagnostic and treatment approach. A history of mania, hypomania, or mixed features can change medication risk and specialist decisions. Anyone with these symptoms should have diagnostic evaluation before selecting a unipolar-depression treatment pathway. VA/DoD.
10. What happens after two unsuccessful antidepressant trials?
The next step is to verify that treatment trials were adequate and that the diagnosis and complicating conditions have been reassessed. Options may include switching, adding psychotherapy, augmentation, and specialist treatments; the choice depends on the detailed history. VA/DoD treatment recommendations.
XVIII. Clinical takeaway
Antidepressants are established treatments for major depressive disorder, with meaningful average benefits and heterogeneous individual outcomes. Their clinical value depends on matching treatment to the diagnosis and person, preparing for adverse effects, evaluating progress, protecting safety, and planning both continuation and eventual discontinuation. A sound decision incorporates patient preferences, scientific evidence, and reliable follow-up.
This article is educational and cannot determine whether a particular reader needs a prescription, medication change, or emergency care. Decisions about starting, tapering, and switching medications require an individual assessment by a qualified clinician. In a life-threatening situation, contact local emergency services.
Related Articles
References
American Academy of Pediatrics. (2018, reaffirmed 2025). Guidelines for Adolescent Depression in Primary Care: Part II. Treatment and Ongoing Management. Pediatrics, 141(3), e20174082. https://doi.org/10.1542/peds.2017-4082.
Cipriani, A., et al. (2018). Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis. The Lancet, 391, 1357–1366. https://doi.org/10.1016/S0140-6736(17)32802-7.
De Luca, B., et al. (2025). Efficacy and tolerability of antidepressants in individuals suffering from physical conditions and depressive disorders: Network meta-analysis. British Journal of Psychiatry, 227, 553–566. https://doi.org/10.1192/bjp.2025.18.
Food and Drug Administration. (2021). Prozac (fluoxetine) prescribing information, including boxed warnings. FDA label.
Food and Drug Administration. (2025). Depression medicines: Uses and risks. FDA.
Food and Drug Administration. (2025). Spravato (esketamine) prescribing information. FDA label.
Henssler, J., et al. (2024). Incidence of antidepressant discontinuation symptoms: A systematic review and meta-analysis. The Lancet Psychiatry, 11, 526–535. https://doi.org/10.1016/S2215-0366(24)00133-0.
Kalfas, M., et al. (2025). Incidence and nature of antidepressant discontinuation symptoms: A systematic review and meta-analysis. JAMA Psychiatry, 82(9), 896–904. https://doi.org/10.1001/jamapsychiatry.2025.1362.
Kamp, C. B., et al. (2025). The risks of adverse events with mirtazapine for adults with major depressive disorder: A systematic review with meta-analysis and trial sequential analysis. BMC Psychiatry, 25, 67. https://doi.org/10.1186/s12888-024-06396-6.
Lewis, G., et al. (2021). Maintenance or discontinuation of antidepressants in primary care. New England Journal of Medicine, 385, 1257–1267. https://doi.org/10.1056/NEJMoa2106356.
National Institute for Health and Care Excellence. (2022). Depression in adults: Treatment and management (NG222). NICE guidance.
National Institute of Mental Health. (n.d.). Depression. NIMH.
Petimar, J., et al. (2024). Medication-induced weight change across common antidepressant treatments: A target trial emulation study. Annals of Internal Medicine, 177(8), 993–1003. https://doi.org/10.7326/M23-2742.
Pillinger, T., et al. (2025). The effects of antidepressants on cardiometabolic and other physiological parameters: A systematic review and network meta-analysis. The Lancet, 406, 2063–2077. https://doi.org/10.1016/S0140-6736(25)01293-0.
U.S. Department of Veterans Affairs and U.S. Department of Defense. (2022). VA/DoD clinical practice guideline for the management of major depressive disorder. VA/DoD MDD guideline.